Bevacizumab: a potential agent for prevention and treatment of hypertrophic scar.
Diao
Jian-Sheng
JS
Xia
Wen-Sen
WS
Guo
Shu-Zhong
SZ
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002056:Burns / Q000150:complications / Q000188:drug therapy*; D017439:Cicatrix, Hypertrophic / Q000188:drug therapy* / Q000517:prevention & control*; D006801:Humans; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab